Kidyaeva, A.V.; Nasyrova, R.F. The role of cariprazine in the prevention and correction of antipsychotic-induced cardiometabolic disorders. Сurrent Therapy of Mental Disorders. 2024, 3:51-57. https://doi.org/10.21265/PSYPH.2024.75.87.005.
DOI: 10.21265/PSYPH.2024.75.87.005
Nasyrova, R.F.; Kidyaeva, A.V.; Grechkina, V.V.; Shnayder, N.A. Personalized approach to prediction and prevention of haloperidol-induced QT interval prolongation: brief review. Pharmacogenetics and Pharmacogenomics. 2024, 1:20-30. https://doi.org/10.37489/2588-0527-2024-1-20-30.
DOI: 10.37489/2588-0527-2024-1-20-30
Pashkovskiy, V.E.; Sofronov, A.G.; Kolchev, S.A.; et al. Prediction of repeated hospitalizations in a psychiatric hospital for patients with paranoid schizophrenia. V.M. Bekhterev review of psychiatry and medical psychology. 2019, 1:34-44. https://doi.org/10.31363/2313-7053-2019-1-34-44 (In Russ.).
DOI: 10.31363/2313-7053-2019-1-34-44 (In Russ.)
Sorokin, M.Y.; Lutova, N.B.; Wied, V.D. Antipsychotic selection strategies: the need for a holistic approach. Zh Nevrol Psikhiatr Im S S Korsakova. 2022, 122(2):73-79. https://doi.org/10.17116/jnevro202212201273 (In Russ.).
DOI: 10.17116/jnevro202212201273 (In Russ.)
Abritalin, E.U.; Aleksandrovsky, Yu.A.; Ananieva, N.I.; et al. Psychiatry: a national guide. Moscow: GEOTAR-Media, 2018. EDN: YMILDU (In Russ.)
Wunderink, L. Personalizing antipsychotic treatment: evidence and thoughts on individualized tailoring of antipsychotic dosage in the treatment of psychotic disorders. Ther Adv Psychopharmacol. 2019, 9:2045125319836566. https://doi.org/10.1177/2045125319836566.
DOI: 10.1177/2045125319836566
Nasyrova, R.F.; Vaiman, E.E.; Repkina, V.V.; et al. Single-nucleotide polymorphisms as biomarkers of antipsychotic-induced akathisia: systematic review. Genes. 2023, 14(3). https://doi.org/10.3390/genes14030616.
DOI: 10.3390/genes14030616
Vaiman, E.E.; Shnayder, N.A.; Zhuravlev, N.M.; et al. Genetic biomarkers of antipsychotic-induced prolongation of the QT interval in patients with schizophrenia. Int J Mol Sci. 2022, 23(24). https://doi.org/10.3390/ijms232415786.
DOI: 10.3390/ijms232415786
Khasanova, A.K.; Dobrodeeva, V.S.; Shnayder, N.A.; et al. Blood and urinary biomarkers of antipsychotic-induced metabolic syndrome. Metabolites. 2022, 12(8). https://doi.org/10.3390/metabo12080726.
DOI: 10.3390/metabo12080726
Mazo, G.E.; Yakovleva, Ya.V. Methods of correction of hyperprolactinemia induced by antipsychotics: current state of the problem and development prospects. V.M. Bekhterev review of psychiatry and medical psychology. 2024, 58(2):107-115. https://doi.org/10.31363/2313-7053-2024-2-972.
DOI: 10.31363/2313-7053-2024-2-972
Sosin, D.N.; Zhuperin, A.A.; Moshevitin, S.Yu.; Burygina, L.A. New prospects for getting over treatment resistant schizophrenia using drugs with adrenergic mechanism of action. Current Therapy of Mental Disorders. 2023, 1:23–30. https://doi.org/10.21265/PSYPH.2023.37.73.003 (In Russ.).
DOI: 10.21265/PSYPH.2023.37.73.003 (In Russ.)
Drug-induced long QT syndrome in psychiatry and neurology / edited by R. F. Nasyrova, N. G. Neznanov, N. A. Shnayder, M. M. Petrova. SPb: DEAN Publishing Center, 2024. 592 pp. ISBN 978-5-6051473-9-8 (In Russ.)
Nasyrova, R.F.; Kidyaeva, A.V.; Petrova, M.M.; Shnayder, N.A. Antipsychotic-induced QT prolongation and Torsade de Pointes in patients with mental disorders: A review. Saf Risk Pharmacother. 2024. https://doi.org/10.30895/2312-7821-2024-410 (In Russ.).
DOI: 10.30895/2312-7821-2024-410 (In Russ.)
Lauschke, V.M.; Ingelman-Sundberg, M. Prediction of drug response and adverse drug reactions: from twin studies to next generation sequencing. Eur J Pharm Sci. 2019, 130:65-77. https://doi.org/10.1016/j.ejps.2019.01.024.
DOI: 10.1016/j.ejps.2019.01.024
Lauschke, V.M.; Zhou, Y.; Ingelman-Sundberg, M. Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. Pharmacol Ther. 2019, 197:122-152. https://doi.org/10.1016/j.pharmthera.2019.01.002.
DOI: 10.1016/j.pharmthera.2019.01.002
van Westrhenen, R.; Aitchison, K.J.; Ingelman-Sundberg, M.; Jukić, M.M. Pharmacogenomics of antidepressant and antipsychotic treatment: how far have we got and where are we going? Front Psychiatry. 2020, 11:94. https://doi.org/10.3389/fpsyt.2020.00094.
DOI: 10.3389/fpsyt.2020.00094
Clinical psychopharmacogenetics / edited by R.F. Nasyrova, N.G. Neznanov. – SPb: DEAN Publishing Center, 2020, 408 pp. ISBN 978-5-6043573-7-8 (In Russ.)
Dobrodeeva, V.S.; Tolmachev, M.Y.; Shnayder, N.A.; Nasyrova, R.F. Influence of single nucleotide variantof gene LEP (rs3828942) on antipsychotic-induced abnormalglucose metabolism in patients with schizophrenia. Сurrent Therapy of Mental Disorders. 2020,1:16-20. https://doi.org/10.21265/PSYPH.2020.37.30.002 (In Russ.).
DOI: 10.21265/PSYPH.2020.37.30.002 (In Russ.)
Grunina, M.N.; Zabotina, A.M.; Zhuravlev, A.S.; et al. Dopamine receptor d2 (drd2) in peripheral blood lymphocytes as biomarker of response to antipsychotic medication. Sci Notes P Pavlov St Petersbg State Med Univ. 2020, 27(1):45-56. https://doi.org/10.24884/1607-4181-2020-27-1-45-56 (In Russ.).
DOI: 10.24884/1607-4181-2020-27-1-45-56 (In Russ.)
Nasyrova, R.F.; Khasanova, A.K.; Altynbekov, K.S.; et al. The role of D-serine and D-aspartate in the pathogenesis and therapy of treatment-resistant schizophrenia. Nutrients. 2022, 14(23). https://doi.org/10.3390/nu14235142.
DOI: 10.3390/nu14235142
Moskaleva, P.V.; Shnayder, N.A.; Dmitrenko, D.V.; et al. Association of TPH1 and TPH2 gene polymorphisms with the risk of developing psychoneurological disorders. Neurosci Behav Physiol. 2022, 52(3):462-469. https://doi.org/10.1007/s11055-022-01260-0.
DOI: 10.1007/s11055-022-01260-0
Vaiman, E.E.; Tumova, M.A.; Guseinova, Z.T.; et al. Influence of single nucleotide polymorphisms of the serotonergic system genes on the occurrence of therapeutic resistance manifestations in patients with schizophrenia. Siberian Herald of Psychiatry and Addiction Psychiatry. 2023, 1 (118):41-49. https://doi.org/10.26617/1810-3111-2023-1(118)-41-49.
DOI: 10.26617/1810-3111-2023-1(118)-41-49
Kaydan, M.A.; Zakharova, N.V.; Zorkina, Ya.A.; Kostyuk, G.P. Search for association of polymorphisms 23.rs6280 of the DRD3 gene, rs4680 of the COMT gene, rs6265 of the gene BDNF with schizophrenia resistant to antipsychotic therapy in Russian populations. Psikhiatriya. 2023, 21(7):14-23. https://doi.org/10.30629/2618-6667-2023-21-7-14-23.
DOI: 10.30629/2618-6667-2023-21-7-14-23
Varnai, R.; Szabo, I.; Tarlos, G.; et al. Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view. Pharmacogenomics J. 2020, 20(3):380-387. https://doi.org/10.1038/s41397-019-0123-z.
DOI: 10.1038/s41397-019-0123-z
Kostyuk, G.P.; Zakharova, N.V.; Reznik, A.M.; et al. Perspectives of the use of pharmacogenetic tests in neurology and psychiatry. Zh Nevrol Psikhiatr Im S S Korsakova. 2019, 119(9):131-135. https://doi.org/10.17116/jnevro2019119091131.
DOI: 10.17116/jnevro2019119091131
Zeier, Z.; Carpenter, L.L.; Kalin, N.H.; et al. Clinical implementation of pharmacogenetic decision support tools for antidepressant drug prescribing. Am J Psychiatry. 2018, 175(9):873-886. https://doi.org/10.1176/appi.ajp.2018.17111282.
DOI: 10.1176/appi.ajp.2018.17111282
Zhuravlev, N.M.; Otmachov, A.P.; Bartasinskaya, A.E. Clinical case of a 36-year-old patient with paranoid schizophrenia and drug-induced QT prolongation. Personalized Psychiatry and Neurology. 2022, 2(2):78-83. https://doi.org/10.52667/2712-9179-2022-2-2-78-83.
DOI: 10.52667/2712-9179-2022-2-2-78-83
Tonk, E.C.M.; Gurwitz, D.; Maitland-van der Zee, A.H.; Janssens, A.C.J.W. Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies. Pharmacogenomics J. 2017, 17(4):386-392. https://doi.org/10.1038/tpj.2016.34.
DOI: 10.1038/tpj.2016.34
Shnayder, N.A.; Abdyrakhmanova, A.K.; Nasyrova, R.F. Oxidation of antipsychotics. Encyclopedia (Basel, 2021). 2022, 2(2):974-989. https://doi.org/10.3390/encyclopedia2020064.
DOI: 10.3390/encyclopedia2020064
Shnayder, N.A.; Khasanova, A.K.; Nasyrova, R.F. First phase of antipsychotic metabolism in the liver: the role of oxidation. Fgen_Fgenom. 2023, (1):15-30. https://doi.org/10.37489/2588-0527-2022-1-15-30.
DOI: 10.37489/2588-0527-2022-1-15-30
Carrascal-Laso, L.; Isidoro-García, M.; Ramos-Gallego, I.; Franco-Martín, M.A. Review: influence of the CYP450 genetic variation on the treatment of psychotic disorders. J Clin Med Res. 2021, 10(18):4275. https://doi.org/10.3390/jcm10184275.
DOI: 10.3390/jcm10184275
Drugbank. Accessed on 10 October 2024. https://go.drugbank.comhttps://go.drugbank.com
State Register of Medicines. Accessed on 7 October 2024. https://grls.rosminzdrav.ru/Default.aspxhttps://grls.rosminzdrav.ru/Default.aspx
Vasiliu O. Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence? Front Psychiatry. 2022, 13:1069432. https://doi.org/10.3389/fpsyt.2022.1069432.
DOI: 10.3389/fpsyt.2022.1069432
Popovic, D.; Nuss, P.; Vieta, E. Revisiting loxapine: a systematic review. Ann Gen Psychiatry. 2015, 14:15. https://doi.org/10.1186/s12991-015-0053-3.
DOI: 10.1186/s12991-015-0053-3
Preda, A.; Shapiro, B.B. A safety evaluation of aripiprazole in the treatment of schizophrenia. Expert Opin Drug Saf. 2020, 19(12):1529-1538. https://doi.org/10.1080/14740338.2020.1832990.
DOI: 10.1080/14740338.2020.1832990
Zhao, M.; Ma, J.; Li, M.; et al. Cytochrome P450 enzymes and drug metabolism in humans. Int J Mol Sci. 2021, 22(23). https://doi.org/10.3390/ijms222312808.
DOI: 10.3390/ijms222312808
Hicks, J.K.; Bishop, J.R.; Sangkuhl, K.; et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015, 98(2):127-134. https://doi.org/10.1002/cpt.147.
DOI: 10.1002/cpt.147
Hicks, J.K.; Bishop, J.R.; Sangkuhl, K.; et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015, 98(2):127-134. https://doi.org/10.1002/cpt.147.
DOI: 10.1002/cpt.147
Caudle, K.E.; Dunnenberger, H.M.; Freimuth, R.R.; et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017, 19(2):215-223. https://doi.org/10.1038/gim.2016.87.
DOI: 10.1038/gim.2016.87
Caudle, K.E.; Dunnenberger, H.M.; Freimuth, R.R.; et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017, 19(2):215-223. https://doi.org/10.1038/gim.2016.87.
DOI: 10.1038/gim.2016.87
Alemayehu, D.; Melisie, G.; Taye, K.; et al. The role of ABC efflux transporter in treatment of pharmaco-resistant schizophrenia: a review article. Clin Pharmacol Biopharm. 2019, 8:189
Qosa, H.; Miller, D.S.; Pasinelli, P.; Trotti, D. Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders. Brain Res. 2015, 1628(Pt B):298-316. https://doi.org/10.1016/j.brainres.2015.07.005.
DOI: 10.1016/j.brainres.2015.07.005
Wijaya, J.; Fukuda, Y.; Schuetz, J.D. Obstacles to brain tumor therapy: key ABC transporters. Int J Mol Sci. 2017, 18(12). https://doi.org/10.3390/ijms1812254445.
DOI: 10.3390/ijms1812254445
Nasyrova, R.F.; Shnayder, N.A.; Osipova, S.M.; et al. Genetic predictors of antipsychotic efflux impairment via blood-brain barrier: role of transport proteins. Genes. 2023, 14(5). https://doi.org/10.3390/genes14051085.
DOI: 10.3390/genes14051085
Luptáková, D.; Vallianatou, T.; Nilsson, A.; et al. Neuropharmacokinetic visualization of regional and subregional unbound antipsychotic drug transport across the blood-brain barrier. Mol Psychiatry. 2021, 26(12):7732-7745. https://doi.org/10.1038/s41380-021-01267-y.
DOI: 10.1038/s41380-021-01267-y
PharmGKB. Accessed on October 20, 2024. https://www.pharmgkb.org/gene/PA267/variantAnnotationhttps://www.pharmgkb.org/gene/PA267/variantAnnotation
Nasyrova, R.; Dobrodeeva, V.; Skopin, S.; et al. Problems and prospects for the implementation of pharmacogenetic testing in real clinical practice in the Russian Federation. Vestnik nevrologii, psihiatrii i nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery). 2020, (3):6-12. https://doi.org/10.33920/med-01-2003-01.
DOI: 10.33920/med-01-2003-01
Lara, D.V.; de Melo, D.O; de Silva, R.A.M.; de Santos, P.C.J.L. Pharmacogenetic testing in psychiatry and neurology: an overview of reviews. Pharmacogenomics. 2021, 22(8):505-513. https://doi.org/10.2217/pgs-2020-0187.
DOI: 10.2217/pgs-2020-0187
Yagudina, R.I.; Serpik, V.G.; Babiy, V.V.; Ugrekhelidze, D.T. Сriteria of efficiency in pharmacoeconomic analysis. Pharmacoeconomics Theory Pract. 2017, 5(3):11-15. https://doi.org/10.30809/phe.3.2017.7.
DOI: 10.30809/phe.3.2017.7
Morris, S.A.; Alsaidi, A.T.; Verbyla, A.; et al. Cost effectiveness of pharmacogenetic testing for drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines: a systematic review. Clin Pharmacol Ther. 2022, 112(6):1318-1328. https://doi.org/10.1002/cpt.2754.
DOI: 10.1002/cpt.2754
Kumar, A.; Kearney, A. The use of pharmacogenetic testing in psychiatry. J Am Assoc Nurse Pract. 2021, 33(11):849-851. https://doi.org/10.1097/JXX.0000000000000666.
DOI: 10.1097/JXX.0000000000000666
Adiukwu, F.; Adesokun, O.; Essien, E.; et al. Pharmacogenetic testing in psychiatry: Perspective on clinical utility. Asian J Psychiatr. 2023, 86:103674. https://doi.org/10.1016/j.ajp.2023.103674.
DOI: 10.1016/j.ajp.2023.103674
Bousman, C.A.; Bengesser, S.A.; Aitchison, K.J.; et al. Review and consensus on pharmacogenomic testing in psychiatry. Pharmacopsychiatry. 2021, 54(1):5-17. https://doi.org/10.1055/a-1288-1061.
DOI: 10.1055/a-1288-1061
Maruf, A.A.; Fan, M.; Arnold, P.D.; et al. Pharmacogenetic testing options relevant to psychiatry in Canada: Options de tests pharmacogénétiques pertinents en psychiatrie au Canada. Can J Psychiatry. 2020, 65(8):521-530. https://doi.org/10.1177/0706743720904820.
DOI: 10.1177/0706743720904820